Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21794041 | 0.97 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL20609536 | 0.92 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL22624080 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL18574296 | 0.84 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL19297891 | 0.81 | ESR1 (0.31) | — | |
| SCHEMBL11185156 | 0.78 | LMNA (0.34) | — | |
| SCHEMBL22624088 | 0.73 | FAAH (0.34) | — | |
| SCHEMBL23118761 | 0.70 | CNR2 (0.36) | — | |
| SCHEMBL21186254 | 0.70 | ESR1 (0.33) | — | |
| SCHEMBL3177257 | 0.69 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | SMN1; SMN2 2491/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | SMN1; SMN2 2491/4885 |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | SMN1; SMN2 3644/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | SMN1; SMN2 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.